825 related articles for article (PubMed ID: 22023342)
1. Explicit review of risperidone long-acting injection prescribing practice.
Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
[TBL] [Abstract][Full Text] [Related]
2. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):61-8. PubMed ID: 22776632
[TBL] [Abstract][Full Text] [Related]
3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
4. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
Pechlivanoglou P; Vehof J; van Agthoven M; de Jong-van den Berg LT; Postma MJ
Clin Ther; 2010 Jan; 32(1):108-18. PubMed ID: 20171417
[TBL] [Abstract][Full Text] [Related]
5. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
[TBL] [Abstract][Full Text] [Related]
6. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
Boaz TL; Constantine RJ; Robst J; Becker MA; Howe AM
J Clin Psychiatry; 2011 Aug; 72(8):1079-85. PubMed ID: 21034690
[TBL] [Abstract][Full Text] [Related]
7. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
9. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.
Aggarwal NK; Sernyak MJ; Rosenheck RA
J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
[TBL] [Abstract][Full Text] [Related]
12. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
De la Gándara J; San Molina L; Rubio G; Rodriguez-Morales A; Hidalgo Borrajo R; Burón JA
Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
Parellada E; Kouniakis F; Siurkute A; Schreiner A; Don L
Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
[TBL] [Abstract][Full Text] [Related]
15. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
[TBL] [Abstract][Full Text] [Related]
16. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
Se Hyun Kim ; Dong Chung Jung ; Yong Min Ahn ; Yong Sik Kim
J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641
[TBL] [Abstract][Full Text] [Related]
17. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.
Taylor DM; Fischetti C; Sparshatt A; Thomas A; Bishara D; Cornelius V
J Clin Psychiatry; 2009 Feb; 70(2):196-200. PubMed ID: 19026261
[TBL] [Abstract][Full Text] [Related]
18. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
Arunpongpaisal S; Srisurapanont M; Kongsakon R; Kitiwattanagul K; Samanwongthai U
J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
[TBL] [Abstract][Full Text] [Related]
19. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
Duncan EJ; Woolson SL; Hamer RM
Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
[TBL] [Abstract][Full Text] [Related]
20. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
Taylor DM; Young CL; Mace S; Patel MX
J Clin Psychiatry; 2004 Aug; 65(8):1076-83. PubMed ID: 15323592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]